<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340506</url>
  </required_header>
  <id_info>
    <org_study_id>CDRB436X2X02B</org_study_id>
    <nct_id>NCT03340506</nct_id>
  </id_info>
  <brief_title>Dabrafenib and/or Trametinib Rollover Study</brief_title>
  <official_title>Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to provide access for patients who are receiving treatment with dabrafenib
      and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs
      or a former GSK-sponsored study who have fulfilled the requirements for the primary
      objective, and who are judged by the investigator as benefiting from continued treatment n
      the parent study as judged by the Investigator at the completion of the parent study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">November 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 9, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combination</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>Clinical and laboratory assessments should be completed based on the local standard of care and physician practice for routine safety monitoring. More frequent examinations may be performed at the Investigator's discretion if medically indicated. Any abnormalities considered clinically significant, induce clinical signs or symptoms, require concomitant therapy or require changes in treatment constitute an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Assessment by investigator</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>To evaluate clinical benefit as assessed by the Investigator</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Melanoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Rare Cancers</condition>
  <condition>High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>dabrafenib and/or trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this study may receive one of the following treatments received in the parent study which are:
Patients who received monotherapy of either of dabrafenib or trametinib solid dose forms
Patients who received combination of dabrafenib and trametinib solid dose forms
Patients who received suspensions of dabrafenib and/or trametinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabrafenib</intervention_name>
    <description>dabrafenib is available in capsules (50mg and 75mg) as well as in powder form for Oral Suspension (10 mg/mL dose) and taken twice a day</description>
    <arm_group_label>dabrafenib and/or trametinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>trametinib is available in tablet (0.125mg, 0.5mg, 2mg dose) as well as in powder form for Oral Solution (0.05mg/mL dose</description>
    <arm_group_label>dabrafenib and/or trametinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or
             combination within a Novartis or former GSK sponsored study which has fulfilled the
             requirements for the primary objective.

          -  In the opinion of the Investigator would benefit from continued treatment.

        Exclusion Criteria:

          -  Patient has been previously permanently discontinued from study treatment in the
             parent protocol.

          -  Patient's indication is commercially available and reimbursed in the local country.

          -  Patient has participated in a combination trial where dabrafenib and/or trametinib was
             dispensed in combination with another study medication.

          -  Patient currently has unresolved toxicities for which dabrafenib and/or trametinib
             dosing has been interrupted in the parent study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tafinlar</keyword>
  <keyword>Mekinist</keyword>
  <keyword>Dabrafenib</keyword>
  <keyword>Trametinib</keyword>
  <keyword>Adult</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Melanoma Stage IV</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Advanced Melanoma</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>NSLC</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>BRAF V600 Mutation</keyword>
  <keyword>BRAF Gene Mutation</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Rare cancers</keyword>
  <keyword>High Grade Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

